Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Allogene Therapeutics, Inc. (ALLO : NSDQ)

• Company Description    Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.? Number of Employees: 361

• Price / Volume Information    Yesterday's Closing Price: $5.32 Daily Weekly Monthly 20 Day Moving Average: 1,649,901 shares Shares Outstanding: 145.84 (millions) Market Capitalization: $775.88 (millions) Beta: 0.77 52 Week High: $17.49 52 Week Low: $4.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -17.52% -20.64% 12 Week -8.12% -14.71% Year To Date -15.42% -23.07%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 210 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-457-2700 fax: - ir@allogene.com http://www.allogene.com

• General Corporate Information    Officers David Chang - President; Chief Executive Officer Arie Belldegrun - Executive Chairman of the Board of Directors Eric Schmidt - Chief Financial Officer Elizabeth Barrett - Director David Bonderman - Director Peer Information Allogene Therapeutics, Inc. (CORR.) Allogene Therapeutics, Inc. (RSPI) Allogene Therapeutics, Inc. (CGXP) Allogene Therapeutics, Inc. (BGEN) Allogene Therapeutics, Inc. (GTBP) Allogene Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 019770106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/23 Next Expected EPS Date: 08/08/23 Share - Related Items Shares Outstanding: 145.84 Most Recent Split Date: (:1) Beta: 0.77 Market Capitalization: $775.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.59 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.31 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 12.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 24.48% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/08/23

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.31 Price/Cash Flow: - Price / Sales: 3,315.72 EPS Growth vs. Year Ago Period: -21.43% vs. Previous Quarter: -3.03% Sales Growth vs. Year Ago Period: -14.75% vs. Previous Quarter: 10.64% ROE 03/31/23 - -50.21 12/31/22 - -43.44 09/30/22 - -37.74 ROA 03/31/23 - -41.36 12/31/22 - -36.79 09/30/22 - -32.58 Current Ratio 03/31/23 - 8.08 12/31/22 - 9.70 09/30/22 - 11.64 Quick Ratio 03/31/23 - 8.08 12/31/22 - 9.70 09/30/22 - 11.64 Operating Margin 03/31/23 - -150,207.69 12/31/22 - -136,885.59 09/30/22 - -126,580.16 Net Margin 03/31/23 - -150,207.69 12/31/22 - -136,885.59 09/30/22 - -126,580.16 Pre-Tax Margin 03/31/23 - -150,207.67 12/31/22 - -136,885.59 09/30/22 - -126,580.18 Book Value 03/31/23 - 4.06 12/31/22 - 4.62 09/30/22 - 5.15 Inventory Turnover 03/31/23 - - 12/31/22 - - 09/30/22 - - Debt-to-Equity 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00 Debt-to-Capital 03/31/23 - 0.00 12/31/22 - 0.00 09/30/22 - 0.00

Powered by Zacks Investment Research ©